CIBC Bancorp USA’s AbCellera Biologics ABCL Stock Holding History

CIBC Bancorp USA’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$69.8K	–	1931
2026 Q1	$69.8K	Buy	+20,000	New	+$72K	﹤0.01%	1703

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CIBC Bancorp USA's ABCL Position: Q2 2026 in Review

CIBC Bancorp USA sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 20,000 shares — an estimated $69.8K sold.

CIBC Bancorp USA first reported a position in ABCL in Q1 2026 and held it in 1 quarter. The position peaked at $69.8K in Q1 2026. 142 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

CIBC Bancorp USA reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
CIBC Bancorp USA sold 20,000 AbCellera Biologics shares in Q2 2026, an estimated $69.8K.
CIBC Bancorp USA first reported a position in AbCellera Biologics in Q1 2026 and held it in 1 quarter.
CIBC Bancorp USA's AbCellera Biologics position peaked at $69.8K in Q1 2026.
142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.